Free Trial
BATS:HELX

Franklin Genomic Advancements ETF (HELX) Price, Holdings, & News

$26.83 -0.29 (-1.08%)
As of 12:24 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Franklin Genomic Advancements ETF (BATS:HELX)

Key Stats

Today's Range
$26.85
$26.99
50-Day Range
$24.14
$30.17
52-Week Range
$23.74
$33.98
Volume
205 shs
Average Volume
3,095 shs
Market Capitalization
$10.73 million
Assets Under Management
$10.89 million
Dividend Yield
N/A
Net Expense Ratio
0.50%
Aggregate Rating
Moderate Buy

ETF Overview

The Franklin Genomic Advancements ETF (HELX) is an exchange-traded fund that is based on the Solactive Genomics index. The fund is an actively managed portfolio of global equity securities of companies relevant to genomic discovery. HELX was launched on Feb 25, 2020 and is managed by Franklin Templeton.

Franklin Genomic Advancements ETF Expenses

TypeHELXTheme ETFsEquity ETFsBATS ETFsAll ETFs
Management Fee0.50%0.57%0.56%0.57%0.53%
Other Expenses0.00%0.57%0.48%0.44%0.52%
Total Expense0.50%0.73%0.72%0.69%0.71%
Fee Waiver0.00%-0.71%-0.49%-0.34%-0.54%
Net Expense0.50%0.60%0.63%0.65%0.60%
Receive HELX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Franklin Genomic Advancements ETF and its competitors with MarketBeat's FREE daily newsletter.

HELX ETF News Headlines

Franklin Emerging Markets UCITS ETF (FLXE)
Franklin Ethereum ETF (EZET)
The Man I Turn to In Times Like This
A storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when publisher Brett Aitken turns to Whitney Tilson—a man CNBC once dubbed “The Prophet.” Tilson just released a new prediction that runs counter to what mainstream finance is telling you.
Franklin U.S. Treasury Bond ETF
See More Headlines

HELX ETF - Frequently Asked Questions

Franklin Genomic Advancements ETF's stock was trading at $28.85 at the beginning of 2025. Since then, HELX stock has decreased by 7.0% and is now trading at $26.8310.
View the best growth stocks for 2025 here
.

Top institutional shareholders of Franklin Genomic Advancements ETF include Halbert Hargrove Global Advisors LLC (0.64%).

Shares of HELX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Franklin Genomic Advancements ETF investors own include Merck & Co., Inc. (MRK), Abiomed (ABMD), Catalent (CTLT), iShares iBonds Dec 2025 Term Muni Bond ETF (IBMN), Net Element (NETE), Novavax (NVAX) and AbbVie (ABBV).

Fund Details

Issuer
Franklin Templeton Investments
Fund Name
Franklin Genomic Advancements ETF
Tax Classification
Regulated Investment Company
Stock Exchange
BATS
Current Symbol
BATS:HELX
Inception Date
2/25/2020
Fund Manager
Matthew J.Moberg, Joyce Lin
Web
N/A
Phone
N/A

Fund Focus

Asset Class
Equity
Benchmark
N/A
Category
Strategy
Focus
Theme
Development Level
Blended Development
Region
Global
Number of Holdings
74

Fund Statistics

Assets Under Management
$10.89 million
Average Daily Volume
$0.00
Discount/Premium
0.02%

Administrator, Advisor and Custodian

Administrator
Franklin Templeton Services, LLC
Advisor
Franklin Advisers, Inc.
Custodian
State Street Bank and Trust Company
Distributor
Franklin Templeton Distributors, Inc.
Transfer Agent
State Street Bank and Trust Company
Trustee
N/A
Lead Market Maker
Citadel

Miscellaneous

Beta
1.15
Creation Unit
50,000
Creation Fee
$200.00
Free Today: Your Guide to Smarter Options Trades Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Top 10 HELX Holdings

HELX Sector Exposure

HELX Industry Exposure


This page (BATS:HELX) was last updated on 5/1/2025 by MarketBeat.com Staff
From Our Partners